Spruce Biosciences, Inc. (SPRBD)
OTCMKTS · Delayed Price · Currency is USD
7.00
-0.50 (-6.67%)
At close: Aug 29, 2025

Spruce Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2020
Net Income
-48.34-53.04-47.92-46.18-42.29-29.54
Upgrade
Depreciation & Amortization
0.030.050.070.070.070.04
Upgrade
Loss (Gain) From Sale of Assets
-000.04--
Upgrade
Loss (Gain) From Sale of Investments
---0.640.020.12-
Upgrade
Stock-Based Compensation
2.575.354.623.633.960.76
Upgrade
Other Operating Activities
-0.360.250.23-0.40.310.07
Upgrade
Change in Accounts Payable
0.13-2.041.91-1.4-0.813.73
Upgrade
Change in Unearned Revenue
-1.3-4.914.91---
Upgrade
Change in Other Net Operating Assets
-4.18-1.623.542.532.76-2.57
Upgrade
Operating Cash Flow
-51.46-55.96-33.28-41.68-35.88-27.52
Upgrade
Capital Expenditures
---0.01-0.01-0.09-0.07
Upgrade
Investment in Securities
--55.7823.7-79.08-
Upgrade
Investing Cash Flow
--55.7823.69-79.17-0.07
Upgrade
Long-Term Debt Issued
----5-
Upgrade
Long-Term Debt Repaid
--1.62-1.62--4.77-
Upgrade
Net Debt Issued (Repaid)
-1.62-1.62-1.62-0.23-
Upgrade
Issuance of Common Stock
0.010.2553.790.080.4693.4
Upgrade
Repurchase of Common Stock
-0.23-0.25-0.31-0.04--
Upgrade
Other Financing Activities
---2.72-0.28-0.05-
Upgrade
Financing Cash Flow
-1.84-1.6249.14-0.240.64181.04
Upgrade
Net Cash Flow
-53.3-57.5971.64-18.23-114.4153.44
Upgrade
Free Cash Flow
-51.46-55.96-33.28-41.69-35.97-27.59
Upgrade
Free Cash Flow Margin
-3961.12%-1139.56%-329.88%---
Upgrade
Free Cash Flow Per Share
-90.22-101.72-64.82-132.90-115.48-345.42
Upgrade
Cash Interest Paid
0.230.230.370.270.210.19
Upgrade
Levered Free Cash Flow
-35.1-38.75-17.52-25.55-20.7-16.48
Upgrade
Unlevered Free Cash Flow
-34.98-38.56-17.22-25.28-20.49-16.28
Upgrade
Change in Working Capital
-5.36-8.5710.361.131.961.16
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.